Jeff Yass’s Aprea Therapeutics APRE Stock Holding History

Jeff Yass’s Portfolio APRE Stock Details APRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-104,300	Closed	-$490K	–	12107
2023 Q4	$490K	Hold	104,300	–	–	﹤0.01%	8712
2023 Q3	$437K	Hold	104,300	–	–	﹤0.01%	8550
2023 Q2	$329K	Sell	104,300 -6,000	-5%	-$22.4K	﹤0.01%	9260
2023 Q1	$491K	Buy	110,300 +103,070	+1,426%	+$761K	﹤0.01%	8615
2022 Q4	$46.3K	Hold	7,230	–	–	﹤0.01%	11438
2022 Q3	$94K	Buy	7,230 +745	+11%	+$13.2K	﹤0.01%	11747
2022 Q2	$96K	Buy	6,485 +225	+4%	+$5.19K	﹤0.01%	11521
2022 Q1	$233K	Buy	6,260 +5,090	+435%	+$209K	﹤0.01%	10865
2021 Q4	$67K	Buy	+1,170	New	+$103K	﹤0.01%	12401
2021 Q3	–	Sell	-2,145	Closed	-$209K	–	12691
2021 Q2	$209K	Buy	2,145 +1,090	+103%	+$101K	﹤0.01%	11510
2021 Q1	$108K	Buy	+1,055	New	+$123K	﹤0.01%	11819

Other funds holding APRE

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Diadema Partners Morristown, New Jersey $791M AUM 245.83% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Jeff Yass's APRE Position: Q2 2026 in Review

Jeff Yass increased its Aprea Therapeutics (APRE) stake by 168% in Q2 2026, buying an estimated $18.3K and bringing the position to 34,939 shares worth $28K. The position accounts for ﹤0.01% of the portfolio, ranked #12981.

Jeff Yass first reported a position in APRE in Q2 2021 and has held it in 10 quarters since. The position peaked at $1.02M in Q3 2021. 28 funds tracked by Wall St. Rank hold APRE as of Q2 2026.

Jeff Yass held 34,939 shares of Aprea Therapeutics worth $28K as of Q2 2026.
Jeff Yass bought 21,921 Aprea Therapeutics shares in Q2 2026, an estimated $18.3K.
Aprea Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #12981 holding.
Jeff Yass first reported a position in Aprea Therapeutics in Q2 2021 and has held it in 10 quarters since.
Jeff Yass's Aprea Therapeutics position peaked at $1.02M in Q3 2021.
28 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.